HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club
NRx Pharmaceuticals (NASDAQ:NRXP) and its subsidiary HOPE Therapeutics conducted an investor workshop at Mar-A-Lago Club focused on HOPE's expansion plans for interventional psychiatry practices. The event, attended by Qualified Institutional Buyers, highlighted several key initiatives:
The company secured a $25 million financing commitment from Smith and Sauer, which is expected to leverage bank financing to secure $100 million in HOPE clinic revenue. The expansion strategy includes plans to add 50 clinics in 2026 and 100 clinics in 2027.
The discussion covered HOPE's mission to build an international network of EBITDA-positive interventional psychiatry clinics, recent clinic acquisitions, and plans for implementing CRM-based technology and telepsychiatry systems. A follow-up meeting is scheduled for late January 2025, expanding to include Accredited Investors.
NRx Pharmaceuticals (NASDAQ:NRXP) e la sua controllata HOPE Therapeutics hanno condotto un workshop per investitori presso il Mar-A-Lago Club, focalizzandosi sui piani di espansione di HOPE per le pratiche di psichiatria interventista. L'evento, a cui hanno partecipato Investitori Istituzionali Qualificati, ha evidenziato diverse iniziative chiave:
L'azienda ha ottenuto un impegno di finanziamento di 25 milioni di dollari da Smith e Sauer, che dovrebbe sfruttare un finanziamento bancario per garantire 100 milioni di dollari di entrate dalle cliniche HOPE. La strategia di espansione prevede l'aggiunta di 50 cliniche nel 2026 e 100 cliniche nel 2027.
La discussione ha riguardato la missione di HOPE di costruire una rete internazionale di cliniche di psichiatria interventista positive in EBITDA, recenti acquisizioni di cliniche e piani per l'implementazione di tecnologie basate su CRM e sistemi di telepsichiatria. Un incontro di follow-up è previsto per la fine di gennaio 2025, ampliando la partecipazione agli Investitori Accreditati.
NRx Pharmaceuticals (NASDAQ:NRXP) y su filial HOPE Therapeutics llevaron a cabo un taller para inversores en el Mar-A-Lago Club, centrado en los planes de expansión de HOPE para las prácticas de psiquiatría intervencionista. El evento, al que asistieron Compradores Institucionales Calificados, destacó varias iniciativas clave:
La empresa aseguró un compromiso de financiación de 25 millones de dólares de Smith y Sauer, que se espera aproveche la financiación bancaria para asegurar 100 millones de dólares en ingresos de las clínicas HOPE. La estrategia de expansión incluye planes para agregar 50 clínicas en 2026 y 100 clínicas en 2027.
La discusión abarcó la misión de HOPE de construir una red internacional de clínicas de psiquiatría intervencionista con EBITDA positivo, adquisiciones recientes de clínicas y planes para implementar tecnología basada en CRM y sistemas de telepsiquiatría. Una reunión de seguimiento está programada para finales de enero de 2025, ampliándose para incluir Inversores Acreditados.
NRx Pharmaceuticals (NASDAQ:NRXP)와 그 자회사 HOPE Therapeutics는 Mar-A-Lago Club에서 HOPE의 개입 정신의학 클리닉 확장 계획에 초점을 맞춘 투자자 워크숍을 진행했습니다. 자격을 갖춘 기관 투자자들이 참석한 이번 행사에서는 여러 주요 이니셔티브가 강조되었습니다:
회사는 Smith와 Sauer로부터 2천5백만 달러의 금융 약정을 확보했으며, 이는 은행 금융을 활용하여 1억 달러의 HOPE 클리닉 수익을 확보할 것으로 예상됩니다. 확장 전략에는 2026년에 50개의 클리닉 추가 및 2027년에 100개의 클리닉 추가 계획이 포함됩니다.
논의에서는 EBITDA-positive 개입 정신의학 클리닉의 국제 네트워크를 구축하려는 HOPE의 미션, 최근 클리닉 인수 및 CRM 기반 기술과 원격 정신의학 시스템 구현 계획이 다뤄졌습니다. 후속 회의는 2025년 1월 말로 예정되어 있으며, 인증된 투자자도 포함될 것입니다.
NRx Pharmaceuticals (NASDAQ:NRXP) et sa filiale HOPE Therapeutics ont organisé un atelier pour investisseurs au Mar-A-Lago Club, axé sur les plans d'expansion de HOPE pour les pratiques de psychiatrie interventionnelle. L'événement, auquel ont assisté des Investisseurs Institutionnels Qualifiés, a mis en lumière plusieurs initiatives clés :
L'entreprise a obtenu un engagement de financement de 25 millions de dollars de Smith et Sauer, qui devrait permettre de mobiliser des financements bancaires pour garantir 100 millions de dollars de revenus pour les cliniques HOPE. La stratégie d'expansion prévoit l'ajout de 50 cliniques en 2026 et 100 cliniques en 2027.
La discussion a porté sur la mission de HOPE de créer un réseau international de cliniques de psychiatrie interventionnelle générant un EBITDA positif, les récentes acquisitions de cliniques et les plans de mise en œuvre de technologies basées sur un CRM et de systèmes de télépsychiatrie. Une réunion de suivi est prévue pour fin janvier 2025, élargissant la participation aux Investisseurs Accrédités.
NRx Pharmaceuticals (NASDAQ:NRXP) und deren Tochtergesellschaft HOPE Therapeutics führten einen Investoren-Workshop im Mar-A-Lago Club durch, der sich auf die Expansionspläne von HOPE für interventionelle Psychiatrie-Praxen konzentrierte. Die Veranstaltung, an der qualifizierte institutionelle Käufer teilnahmen, stellte mehrere Schlüsseliniziativen vor:
Das Unternehmen sicherte sich ein Finanzierungsengagement von 25 Millionen US-Dollar von Smith und Sauer, das voraussichtlich Bankfinanzierungen nutzen wird, um 100 Millionen US-Dollar an HOPE-Klinikumsätzen zu sichern. Die Expansionsstrategie umfasst Pläne zur Eröffnung von 50 Kliniken im Jahr 2026 und 100 Kliniken im Jahr 2027.
Die Diskussion behandelte die Mission von HOPE, ein internationales Netzwerk von EBITDA-positiven interventionellen Psychiatrieklinken aufzubauen, jüngste Klinikübernahmen und Pläne zur Implementierung von CRM-basierter Technologie und Telepsychiatriesystemen. Ein Folgetreffen ist für Ende Januar 2025 geplant, bei dem auch akkreditierte Investoren einbezogen werden.
- Secured $25 million financing commitment from Smith and Sauer
- Projected $100 million in clinic revenue stream
- Aggressive expansion plans for 50 clinics in 2026 and 100 in 2027
- Focus on EBITDA-positive clinic acquisitions
- None.
Insights
The investor workshop at Mar-a-Lago represents a strategic move to expand HOPE Therapeutics' mental health clinic network, backed by
The focus on EBITDA-positive clinics and non-dilutive financing demonstrates a financially prudent approach to expansion. The integration of CRM-based technology and telepsychiatry infrastructure could create operational efficiencies and scalability across the network. What's particularly noteworthy is the company's target market - addressing suicidal depression and PTSD, especially in military/veteran communities, which represents a significant unmet medical need with stable reimbursement pathways.
The presence of Qualified Institutional Buyers and planned follow-up meetings with additional Accredited Investors suggests growing institutional interest in the mental health sector. However, investors should note that while the
The workshop signals a sophisticated approach to capital raising and market expansion. By hosting at Mar-a-Lago and targeting Qualified Institutional Buyers, NRXP is positioning itself to attract high-net-worth investors while maintaining SEC compliance. The planned follow-up meeting including Accredited Investors suggests a well-structured fundraising strategy.
The business model's focus on acquiring EBITDA-positive clinics reduces operational risk and suggests a path to profitability. The technology integration strategy through CRM and telepsychiatry platforms indicates potential for creating economies of scale and improving operational efficiency. This could lead to better margins and more attractive acquisition multiples for future clinic purchases.
For a company with a market cap of
The event was attended by Qualified Institutional Buyers as defined by the Securities and Exchange Commission and included Jonathan Javitt, MD, MPH, Chairman and CEO of NRx together with Dallas Sauer, Founder of Smith and Sauer, the private investment firm that recently committed to invest in both NRx and HOPE. No formal meetings were conducted with members of the incoming administration.
Key areas of investor discussions included:
- HOPE's mission to build an international network of best-in class, EBITDA positive, interventional psychiatry clinics
$25 million $100 million - Recently announced progress for HOPE's initial clinic acquisitions
- Potential mechanisms for follow-on non-dilutive financing to expand HOPE's network by an additional 50 clinics in 2026 and 100 clinics in 2027
- Plans for integration of new technologies and a CRM-based information technology and telepsychiatry umbrella to span the HOPE network
Based on the results of today's meeting, NRx has been invited to return to Mar-A-Lago for an expanded meeting during the last week of January 2025 that will include both Qualified Institutional Buyers and Accredited Investors. Individuals interested in attending are invited to contact Matthew Duffy, Co-CEO of HOPE Therapeutics.
"We were gratified by the enthusiastic response and inciteful questions we received from this group of sophisticated attendees and look forward to future discussions," said Jonathan Javitt, MD MPH, Founder, Chairman & CEO of NRx, and Co-CEO HOPE Therapeutics. "Our mission to treat and prevent suicidality in our society in general, and our military/veteran communities in particular, clearly resonated with those who joined us this evening."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding closing the acquisition of Kadima and obtaining financing necessary to consummate the acquisition. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-conduct-investor-workshop-at-the-mar-a-lago-club-302347792.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the value of Smith and Sauer's investment commitment to NRXP and HOPE Therapeutics?
How many clinics does HOPE Therapeutics plan to add in 2026 and 2027?
What is HOPE Therapeutics' main business focus for NRXP?
What technology integration plans does HOPE Therapeutics have for its clinic network?
